当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Snehal S Manekar, Ravindrakumar L Bakal, Ankush R Turankar
Aim of study: Dengue virus (DENV) causes a clinical infection called dengue hemorrhagic fever (DHF). Millions of people are impacted by this condition. However, there is currently no specific medication available to stop it. Despite having recently received approval for use in preventing illness, a vaccination against some dengue virus (DENV) serotypes was proven to be ineffective. Some preventative methods utilizing plant extracts demonstrated some encouraging ovicidal action against Aedes aegypti.
Summary: Some antiviral medications are being tested in clinical settings to treat dengue fever, but the results have not yet been reported or validated. Numerous researches have revealed that the possibility of using compounds with plant origins could be excellent agents for the creation of secure and effective treatments for certain illnesses. This review provides scientifically validated knowledge on plants used in the treatment and management of dengue fever along with phytoconstituents responsible for the activity and type of solvent used to extract it.